Cargando…

Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah

BACKGROUND: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. OBJECTIVES: Compare the state of immunity to SARS-CoV-2 among h...

Descripción completa

Detalles Bibliográficos
Autores principales: Housawi, Abdulrahman A., Qazi, Shazada Junaid S., Jan, Abdulhalem A., Osman, Rashid A., Alshamrani, Mashil M., AlFaadhel, Talal A., AlHejaili, Fayez F., Al-Tawfiq, Jaffar A., Wafa, Ahmed A., Hamza, Abdulmageed E., Hassan, Moustafa A., Alharbi, Suliman A., Albasheer, Hamza, Almohmmdi, Majed M., Alsisi, Salem A., Mankowski, Michal, Van de Klundert, Joris, Alhelal, Amal M., Sala, Fatima H., Kheyami, Ali, Alhomayeed, Bader A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357293/
https://www.ncbi.nlm.nih.gov/pubmed/35933611
http://dx.doi.org/10.5144/0256-4947.2022.229
_version_ 1784763678730485760
author Housawi, Abdulrahman A.
Qazi, Shazada Junaid S.
Jan, Abdulhalem A.
Osman, Rashid A.
Alshamrani, Mashil M.
AlFaadhel, Talal A.
AlHejaili, Fayez F.
Al-Tawfiq, Jaffar A.
Wafa, Ahmed A.
Hamza, Abdulmageed E.
Hassan, Moustafa A.
Alharbi, Suliman A.
Albasheer, Hamza
Almohmmdi, Majed M.
Alsisi, Salem A.
Mankowski, Michal
Van de Klundert, Joris
Alhelal, Amal M.
Sala, Fatima H.
Kheyami, Ali
Alhomayeed, Bader A.
author_facet Housawi, Abdulrahman A.
Qazi, Shazada Junaid S.
Jan, Abdulhalem A.
Osman, Rashid A.
Alshamrani, Mashil M.
AlFaadhel, Talal A.
AlHejaili, Fayez F.
Al-Tawfiq, Jaffar A.
Wafa, Ahmed A.
Hamza, Abdulmageed E.
Hassan, Moustafa A.
Alharbi, Suliman A.
Albasheer, Hamza
Almohmmdi, Majed M.
Alsisi, Salem A.
Mankowski, Michal
Van de Klundert, Joris
Alhelal, Amal M.
Sala, Fatima H.
Kheyami, Ali
Alhomayeed, Bader A.
author_sort Housawi, Abdulrahman A.
collection PubMed
description BACKGROUND: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. OBJECTIVES: Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff. DESIGN: Cross-sectional study with a prospective follow-up period. SETTING: Hemodialysis centers in Madinah region. PATIENTS AND METHODS: We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity. MAIN OUTCOME MEASURES: SARS-CoV-2 positivity using immunoglobulin G (IgG) levels SAMPLE SIZE: 830 participants, 677 patients and 153 dialysis centers staff as controls. RESULTS: Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively (P=.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG (P<.0001). Surprisingly, positivity was also center-dependent. In a multivariable logistic regression, a history of infection and related symptoms contributed significantly to developing immunity. CONCLUSION: The high prevalence of SARS-CoV-2 antibody among hemodialysis patients and previously asymptomatic staff suggested past asymptomatic infection. Some centers showed more immunity effects than others. LIMITATIONS: Unable to collect four samples for each participant; limited to one urban center. CONFLICT OF INTEREST: None.
format Online
Article
Text
id pubmed-9357293
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher King Faisal Specialist Hospital and Research Centre
record_format MEDLINE/PubMed
spelling pubmed-93572932022-08-30 Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah Housawi, Abdulrahman A. Qazi, Shazada Junaid S. Jan, Abdulhalem A. Osman, Rashid A. Alshamrani, Mashil M. AlFaadhel, Talal A. AlHejaili, Fayez F. Al-Tawfiq, Jaffar A. Wafa, Ahmed A. Hamza, Abdulmageed E. Hassan, Moustafa A. Alharbi, Suliman A. Albasheer, Hamza Almohmmdi, Majed M. Alsisi, Salem A. Mankowski, Michal Van de Klundert, Joris Alhelal, Amal M. Sala, Fatima H. Kheyami, Ali Alhomayeed, Bader A. Ann Saudi Med Original Article BACKGROUND: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients. OBJECTIVES: Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff. DESIGN: Cross-sectional study with a prospective follow-up period. SETTING: Hemodialysis centers in Madinah region. PATIENTS AND METHODS: We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity. MAIN OUTCOME MEASURES: SARS-CoV-2 positivity using immunoglobulin G (IgG) levels SAMPLE SIZE: 830 participants, 677 patients and 153 dialysis centers staff as controls. RESULTS: Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively (P=.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG (P<.0001). Surprisingly, positivity was also center-dependent. In a multivariable logistic regression, a history of infection and related symptoms contributed significantly to developing immunity. CONCLUSION: The high prevalence of SARS-CoV-2 antibody among hemodialysis patients and previously asymptomatic staff suggested past asymptomatic infection. Some centers showed more immunity effects than others. LIMITATIONS: Unable to collect four samples for each participant; limited to one urban center. CONFLICT OF INTEREST: None. King Faisal Specialist Hospital and Research Centre 2022-07 2022-08-04 /pmc/articles/PMC9357293/ /pubmed/35933611 http://dx.doi.org/10.5144/0256-4947.2022.229 Text en Copyright © 2022, Annals of Saudi Medicine, Saudi Arabia https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). The details of which can be accessed at http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Article
Housawi, Abdulrahman A.
Qazi, Shazada Junaid S.
Jan, Abdulhalem A.
Osman, Rashid A.
Alshamrani, Mashil M.
AlFaadhel, Talal A.
AlHejaili, Fayez F.
Al-Tawfiq, Jaffar A.
Wafa, Ahmed A.
Hamza, Abdulmageed E.
Hassan, Moustafa A.
Alharbi, Suliman A.
Albasheer, Hamza
Almohmmdi, Majed M.
Alsisi, Salem A.
Mankowski, Michal
Van de Klundert, Joris
Alhelal, Amal M.
Sala, Fatima H.
Kheyami, Ali
Alhomayeed, Bader A.
Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah
title Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah
title_full Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah
title_fullStr Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah
title_full_unstemmed Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah
title_short Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah
title_sort prevalence of anti-sars-cov-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from madinah
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357293/
https://www.ncbi.nlm.nih.gov/pubmed/35933611
http://dx.doi.org/10.5144/0256-4947.2022.229
work_keys_str_mv AT housawiabdulrahmana prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT qazishazadajunaids prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT janabdulhalema prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT osmanrashida prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT alshamranimashilm prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT alfaadheltalala prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT alhejailifayezf prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT altawfiqjaffara prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT wafaahmeda prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT hamzaabdulmageede prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT hassanmoustafaa prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT alharbisulimana prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT albasheerhamza prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT almohmmdimajedm prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT alsisisalema prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT mankowskimichal prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT vandeklundertjoris prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT alhelalamalm prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT salafatimah prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT kheyamiali prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah
AT alhomayeedbadera prevalenceofantisarscov2antibodyinhemodialysisfacilitiesacrosssectionalmulticenterstudyfrommadinah